Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	 May 11, 2012, April 6, 2015

Sandostatin LAR® Depot (octreotide acetate for injectable suspension)

LENGTH OF AUTHORIZATION: Up to three months (as per prescription)

REVIEW CRITERIA:

- Patient must be ≥ 6 years old.
- Patient has tried and tolerated octreotide (Sandostatin) injection prior to use of Sandostatin LAR. The initiation of Sandostatin LAR therapy must be preceded by octreotide injection for a minimum of two weeks (refer to DOSING and ADMINISTRTATION).
- Diagnosis of Acromegaly with inadequate response to or ineligible for surgery, or radiation **OR**
- Patient has severe diarrhea/flushing episodes associated with carcinoid tumors, **OR**
- Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP)-secreting tumors.

DOSING and ADMINISTRATION:

- Patients not currently receiving octreotide injection subcutaneously:
  - Acromegaly: Octreotide 50 mcg three times daily subcutaneously- for 2 weeks followed by Sandostatin LAR 20 mg intragluteally every 4 weeks for 3 months.
  - Carcinoid Tumors and VIPomas: Octreotide injection subcutaneously 100-600 mcg/day in 2-4 divided doses for 2 weeks followed by Sandostatin LAR 20 mg every 4 weeks for 2 months (Note: doses between 10 mg and 30 mg have been studied, doses higher than 30 mg are not recommended).
- Patients currently receiving Sandostatin Injection subcutaneously:
  - Acromegaly: 20 mg every 4 weeks for 3 months.
  - Carcinoid Tumors and VIPomas: 20 mg every 4 weeks for 2 months (Note: doses between 10 mg and 30 mg have been studied, doses higher than 30 mg are not recommended).